Yahoo Finance·2025-11-02 10:05Company Overview - Acrivon Therapeutics is a clinical-stage biotech company focused on precision oncology, utilizing its proprietary Generative Phosphoproteomics AP3 platform to identify which patients are most likely to benefit from specific therapies [2][4] - The company has advanced two drug candidates into human clinical trials, with ACR-368 being its lead program [1][8] Drug Candidates - ACR-368 is a selective CHK1/CHK2 inhibitor currently in a registrational-intent Phase 2b trial for recurrent, high-grade endometrial cancer, showing encouraging early clinical readouts, particularly in OncoSignature-positive patients [1][7] - ACR-2316 is a dual WEE1/PKMYT1 inhibitor undergoing a Phase 1 monotherapy dose-escalation study, with preclinical data indicating strong single-agent activity and an ongoing confirmed partial response in a patient with endometrial cancer [8][10] Regulatory Designations - ACR-368 has received FDA Fast Track designation as a monotherapy for ovarian and endometrial cancer, while its companion diagnostic, OncoSignature, has been granted Breakthrough Device status [7][10] Market Potential - ACR-2316's positive emerging profile could potentially add approximately $150 million in market capitalization, with analysts noting its best-in-class potential due to its dual-targeting approach [10][11] - Acrivon’s stock, currently trading at $1.99, has a price target of $13, indicating a potential upside of 553% [9][12] Analyst Sentiment - The broader analyst consensus for Acrivon is a Strong Buy, with 6 Buy ratings and an average price target of $11.75, suggesting a potential upside of 490% over the next year [12]